Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven R Hwang

Showing results (11-20 of 21) with videos related to

Pageof 3
Sort By:
Blood Advances|February 18, 2025
Comparison of outcomes in postinduction strategies for primary central nervous system lymphoma: a Mayo Clinic experienceSteven R Hwang, Richard C Godby, Brianna J Negaard, et al.
Blood|July 2, 2013
Integrated phosphoproteomic and metabolomic profiling reveals NPM-ALK-mediated phosphorylation of PKM2 and metabolic reprogramming in anaplastic large cell lymphomaScott R P McDonnell, Steven R Hwang, Delphine Rolland, et al.
Blood Advances|August 27, 2021
Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphomaVictor M Orellana-Noia, Krista Isaac, Mary-Kate Malecek, et al.
Blood Advances|January 11, 2024
Patterns of progression after immune checkpoint inhibitors for Hodgkin lymphoma: implications for radiation therapyJessica F Burlile, Kelsey M Frechette, William G Breen, et al.
Leukemia|December 10, 2024
Incidence of Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma in the targeted therapy eraPaul J Hampel, Kari G Rabe, Yucai Wang, et al.
Blood Advances|August 21, 2023
Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphomaRaphael E Steiner, Steven R Hwang, Arushi Khurana, et al.
Blood Cancer Journal|February 20, 2025
Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLLAdam S Kittai, Ying Huang, Sarah Miller, et al.
Blood Advances|May 13, 2024
The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomasRahul S Bhansali, Fredrik Ellin, Thomas Relander, et al.
Blood Advances|February 24, 2026
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphomaYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Blood Advances|December 11, 2025
Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell LymphomaYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Pageof 3

Showing results (11-20 of 21) with videos related to

Sort By:
Pageof 3
Blood Advances|February 18, 2025
Comparison of outcomes in postinduction strategies for primary central nervous system lymphoma: a Mayo Clinic experienceSteven R Hwang, Richard C Godby, Brianna J Negaard, et al.
Blood|July 2, 2013
Integrated phosphoproteomic and metabolomic profiling reveals NPM-ALK-mediated phosphorylation of PKM2 and metabolic reprogramming in anaplastic large cell lymphomaScott R P McDonnell, Steven R Hwang, Delphine Rolland, et al.
Blood Advances|August 27, 2021
Multicenter analysis of geriatric fitness and real-world outcomes in older patients with classical Hodgkin lymphomaVictor M Orellana-Noia, Krista Isaac, Mary-Kate Malecek, et al.
Blood Advances|January 11, 2024
Patterns of progression after immune checkpoint inhibitors for Hodgkin lymphoma: implications for radiation therapyJessica F Burlile, Kelsey M Frechette, William G Breen, et al.
Leukemia|December 10, 2024
Incidence of Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma in the targeted therapy eraPaul J Hampel, Kari G Rabe, Yucai Wang, et al.
Blood Advances|August 21, 2023
Impact of cumulative dose of brentuximab vedotin on outcomes of frontline therapy for advanced-stage Hodgkin lymphomaRaphael E Steiner, Steven R Hwang, Arushi Khurana, et al.
Blood Cancer Journal|February 20, 2025
Outcomes of patients with Richter transformation who received no prior chemoimmunotherapy for their CLLAdam S Kittai, Ying Huang, Sarah Miller, et al.
Blood Advances|May 13, 2024
The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomasRahul S Bhansali, Fredrik Ellin, Thomas Relander, et al.
Blood Advances|February 24, 2026
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphomaYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Blood Advances|December 11, 2025
Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell LymphomaYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Pageof 3